Safety and effectiveness of a new DNA repair-targeting pill for advanced cancers
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new pill called DAT-2645 for people with advanced solid tumors that have a specific DNA repair problem (like a BRCA gene change). It aims to see if the drug is safe and effective when standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic cancer that has not responded to standard treatments or you cannot take them.
- A lab test shows your tumor has a defect in DNA repair (called a DDR deficiency, like a BRCA mutation).
- You have at least one tumor that can be measured on a scan (like a CT or MRI).
- You are generally well enough to be up and about (ECOG score 0-2) and have a life expectancy of at least 3 months.
- You have not had a PARG inhibitor before, and your brain tumors (if any) are stable and not requiring steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests the drug Dato-DXd (alone or with other cancer medicines) in people with advanced solid tumors. It looks for tumor shrinkage and how safely the treatment can be given.
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new oral drug, DAT-1604, for people with advanced solid tumors who have run out of standard options. The goal is to see if it is safe, how the body processes it, and whether it can shrink tumors.
This Phase I/II trial tests an investigational treatment in people with advanced solid tumors that have grown despite standard therapy, or where standard options aren’t available. In later Phase II, the trial mainly enrolls patients whose tumor shows a specific DNA repair problem (DDR defect).
This trial tests an experimental drug (SPR1020) for people with advanced solid tumors that have not responded to standard treatments, especially those with BRCA or related gene mutations. The drug is taken by mouth and the study aims to find the right dose and see if it helps shrink tumors.
This study tests a new drug called DAT-2645 for ovarian cancer patients with specific genetic changes (BRCA mutations or HRD-positive status) who haven't responded well to standard treatments. The drug may help slow or stop cancer growth in patients whose tumors have DNA-repair problems.
Hear when a new Solid Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.